To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
Completed · Phase 1
Conditions studied: Solid Tumours
In brief
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in subjects with renal impairment and healthy subjects
Key facts
- Study ID
- NCT02063204
- Run by
- AstraZeneca
- People needed
- 24
- Starts
- 2014-03-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2015-06-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.